Pfizer's Macugen Approved in Europe
Posted on: Saturday, 4 February 2006, 03:03 CST
The European Commission has granted marketing approval for Pfizer's eye drug, Macugen, for the treatment of wet age related macular degeneration, a disease that causes severe vision loss.
Macugen, co-developed by Pfizer and OSI Pharmaceuticals, is the first treatment to target the underlying disease process and has been proven to help preserve visual acuity in patients with wet age related macular degeneration (AMD). Clinical studies showed that Macugen prevented severe vision loss at twice the rate of standard care, which included photodynamic therapy.
"Macugen is the first therapy indicated in Europe for the treatment of all types of wet AMD, regardless of lesion subtype, size or visual acuity," said Dr Joseph Feczko, Pfizer's chief medical officer.
Wet AMD is a chronic, progressive disease of the macula, the central portion of the retina responsible for sight. Central vision is impaired when abnormal blood vessel growth beneath the macula, known as choroidal neovascularization, causes bleeding and other fluid accumulation in the retina.
Source: Datamonitor
Related Articles
- ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
- Resolvyx Compounds Show Promise In Treatment of Ocular Disease
- Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to Be Presented at ARVO
- Research and Markets: Does the Treatment of Huntington's Disease Represent a Commercial Opportunity?
- International Movement Disorder Specialists Receive New Information About the Use of Once-Daily AZILECT(R) in the Treatment of Parkinson's Disease
- Neurochem's New Agent Will Become the Clinical Gold Standard for the Treatment of Alzheimer's Disease in 2008
- Teva Neuroscience Announces AZILECT(R) Is Now Available in Pharmacies - the First, Once-Daily Treatment for Parkinson's Disease
- TorreyPines Therapeutics Initiates Phase I Clinical Trial of NGX267 for the Treatment of Alzheimer's Disease
- Tanox to Acquire Antibodies From Sunol Molecular Corp. For Potential Treatment of Inflammatory Disease, Cancer
- New Treatments for Alzheimer's Disease From Rockefeller Institute
 |
 |
User Comments (0)
RSS Feeds